ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

blonca9
20 hours ago
1 min read

Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps.

Recent Posts

See All

ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight